MAP2K7 and malignant peripheral nerve sheath tumor: The ongoing SARC031 clinical trial (NCT03433183) combines the MEK inhibitor Selumetinib with the mTOR inhibitor Sirolimus in unresectable or metastasized MPNST patients and is expected to complete completion in the near future (Sarcoma Alliance for Research through C, United States Department of D, AstraZeneca 2023).